Navigation Links
Mayo Clinic urologists present findings at American Urological Association Annual Meeting
Date:5/23/2012

1999�.

Regardless of treatment method, "approximately one-third of patients undergoing a surgical procedure for stones will experience a recurrence. Patients with a previous history of stones, prior stone surgery, and positive family history are at increased risk," says lead author Amy Krambeck M.D., a Mayo Clinic urologist.

Patients having shock wave lithotripsy were at highest risk of recurrence, while stones were least likely to return in those receiving percutaneous nephrolithotomy. Dr. Krambeck says patients and doctors should focus on treatment options most likely to leave the patient stone free with the least invasive and fewest surgical interventions.

Three studies support C-11 choline PET/CT scans as prostate cancer evaluation tool
Embargoed until 8 a.m. ET, Wednesday, May 23

Recent European studies have suggested that C-11 choline positron emission tomography/ computerized tomography scans may be used as an evaluation and therapeutic tool in prostate cancer. The results of three Mayo Clinic studies validate findings in Europe and expand the potential use of C-11 choline PET scans.

One study found that C-11 choline PET/CT scans can be used as an evaluation tool rather than multiple X-rays, but are not necessarily better. The two additional Mayo studies support the favorable claims made in recent medical literature about the use of PET scans to evaluate patients with recurrent prostate cancer. These findings are important because distinguishing localized disease recurrence from systemic recurrence is a vital step in optimizing treatment following primary treatment failure.

"Taken together, the three studies represent an important validation of the C-11 choline PET/CT scan as an evaluation tool for patients with prostate cancer," says Jeffrey Karnes, M.D., senior author of all three papers. "We believe the use of these scans can improve the evaluation and treatment of this common form
'/>"/>

Contact: Joe Dangor
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
Source:Eurekalert

Page: 1 2 3 4

Related medicine news :

1. Canada should significantly increase its funding of randomized clinical trials
2. Breast cancer clinical trial tests combo of heat shock protein inhibitor and hormonal therapy
3. Mayo Clinic: Standard heart disease risk tools underrate danger in rheumatoid arthritis
4. Experts call for clinical trials to test non-skeletal benefits of vitamin D
5. Clinical news alert: Journal of the American Academy of Orthopaedic Surgeons May highlights
6. Mayo Clinic researchers discover biomarkers for prostate cancer detection, recurrence
7. Automated insulin dosage titration system demonstrates positive clinical study results
8. Mayo Clinic: Exhaustion renders immune cells less effective in cancer treatment
9. Analysis Finds Clinical Trials Often Small, of Poor Quality
10. URMC clinical trial tests new regimen for hypertension
11. Mayo Clinic: Obesity epidemic fueling rise in rheumatoid arthritis among women
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... ... ... article published August 12 by International Business Times, a new bill was signed ... in cases meant to decide if a police officer used deadly or excessive force in ... and New York City that absolved police officers of charges in the deaths of two ...
(Date:9/2/2015)... ... September 02, 2015 , ... Specifically, ... the news recently following a decision by the Centers for Medicare & Medicaid ... to average approximately $71,000 or roughly 40% of its headline-grabbing $178,000 price tag. ...
(Date:9/2/2015)... ... September 02, 2015 , ... RxNT , an ... of its enhanced, cloud-based mobile ePrescribing application. The release of this enhanced iPhone ... usability. A leader in health technology, RxNT was one of the first to ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... intermediate or final products. Automating sample handling makes density measurements more efficient and ... each step of the automated workflow and the advantages compared to manual sample ...
(Date:9/2/2015)... ... 2015 , ... A UPMC and University of Pittsburgh Schools ... a premier center for treatment of and research into hereditary hemorrhagic telangiectasia (HHT), ... , Cure HHT, previously known as The HHT Foundation International, has designated ...
Breaking Medicine News(10 mins):Health News:Article on Recent Grand Jury Law Brings Increased Accountability to Wrongful Death Cases, says the Law Offices of Burg & Brock 2Health News:Article on Recent Grand Jury Law Brings Increased Accountability to Wrongful Death Cases, says the Law Offices of Burg & Brock 3Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 2Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 3Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 4Health News:RxNT Releases Enhanced ePrescribing iPhone App to Improve Prescriber Usability 2Health News:New Video from METTLER TOLEDO Shows the Advantages of Sample Handling Automation in Density Determination 2Health News:New Video from METTLER TOLEDO Shows the Advantages of Sample Handling Automation in Density Determination 3Health News:UPMC-University of Pittsburgh Named Center of Excellence for Rare Disorder 2Health News:UPMC-University of Pittsburgh Named Center of Excellence for Rare Disorder 3Health News:UPMC-University of Pittsburgh Named Center of Excellence for Rare Disorder 4
... BEIJING, June 26 /PRNewswire-Asia/ -- RainEarth Inc.,(OTC Bulletin ... China, Beijing RainEarth Technology Co. Ltd., ("China RainEarth"),has obtained ... that aid in manufacturing blood dialysis. , ... for patents for its core,technology with the State Intellectual ...
... HOUSTON, June 26 The Breast Center at Houston Northwest ... the United States -- and one in Texas -- to ... by the National Quality Measures for Breast Centers (NQMBC) Program(TM). ... measure performance of interdisciplinary breast care nationwide. The designation is ...
... ... in Omaha list for the second straight year. The list is sponsored by the Greater Omaha ... an Omaha business. , ... June 26, 2009 -- Healthcare staffing company Medical Solutions has landed on the ...
... DC (26 June, 2009) Combating high blood pressure ... enjoyed reductions in cardiovascular disease over recent decades, Latin ... published in the journal Therapeutic Advances in Cardiovascular ... the increase in many Latin American countries, a situation ...
... Caraco Pharmaceutical Laboratories, Ltd. (NYSE Amex: CPD ... the Food and Drug Administration, today arrived and seized ... also included ingredients held at these same facilities. The ... in May 2009, found unresolved violations of cGMP requirements ...
... Texas, June 25 Torchmark Corporation (NYSE: TMK ... $300 million in aggregate principal amount of 9.25% Senior Notes ... to close on June 30, 2009, subject to the satisfaction ... offering will be used for the repayment of the $99.45 ...
Cached Medicine News:Health News:RainEarth Obtains Patent Approvals for Its Core Technology 2Health News:RainEarth Obtains Patent Approvals for Its Core Technology 3Health News:The Breast Center at Houston Northwest Medical Center Receives Prestigious National Award 2Health News:The Breast Center at Houston Northwest Medical Center Receives Prestigious National Award 3Health News:Healthcare Staffing Company Medical Solutions Named Among "2009 Best Places to Work in Omaha" 2Health News:Healthcare Staffing Company Medical Solutions Named Among "2009 Best Places to Work in Omaha" 3Health News:Healthcare Staffing Company Medical Solutions Named Among "2009 Best Places to Work in Omaha" 4Health News:Latin America must cut blood pressure to thrive 2Health News:Latin America must cut blood pressure to thrive 3Health News:Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Action 2Health News:Torchmark Prices Senior Notes Offering 2
(Date:9/2/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/6mlrvg/an_introduction ) has ... to Medical Device Software: Regulations and Requirements (London, ... their offering. This course will ... requirements that apply to Medical Device Software. The ... examples and state-of- the-art practices identified from Notified ...
(Date:9/2/2015)... Sept. 2, 2015 Research and Markets ... Jain PharmaBiotech,s new report "Drug Delivery in ... Companies" to their offering. ... the BBB have opened new avenues and possibilities ... carrier or transport systems, enzymes, and receptors that ...
(Date:9/2/2015)... 2, 2015  Boca Raton Regional Hospital,s ... performing ultra-minimally invasive left atrial appendage ligation for ... as Coumadin, Xarelto or Effient. Dr. Cartledge, who ... is one of a select group of surgeons ... microscopic incisions in order to seal off the ...
Breaking Medicine Technology:An Introduction to Medical Device Software: Regulations and Requirements Course - London, UK - November 2-3, 2015 2Drug Delivery in Central Nervous System Diseases - Technologies, Markets and Companies Report 2015-2024 2Drug Delivery in Central Nervous System Diseases - Technologies, Markets and Companies Report 2015-2024 3Boca Regional Introduces Ultra-Minimally Invasive Surgical Procedure for Atrial Fibrillation Patients 2Boca Regional Introduces Ultra-Minimally Invasive Surgical Procedure for Atrial Fibrillation Patients 3
... FDA for Stand-Alone Therapy in Q1 2008, SAN ... ) and Eli Lilly and Company (NYSE: LLY ... with type 2 diabetes who were,unable to achieve glycemic ... either monotherapy (stand-alone) BYETTA(R) (exenatide),injection taken twice daily or ...
... Company to Continue Focus on Pipeline and Haptoglobin ... Synvista Therapeutics,Inc. (Amex: SYI ) today announced ... and 203) of SYI-2074 in Type 2 diabetic ... target of Synvista,s,proprietary haptoglobin variant test currently under ...
Cached Medicine Technology:Monotherapy BYETTA(R) (exenatide) Injection Study Results Presented at ADA 2008 Showed Adults with Type 2 Diabetes Experienced Improved Glycemic Control and Weight Loss 2Monotherapy BYETTA(R) (exenatide) Injection Study Results Presented at ADA 2008 Showed Adults with Type 2 Diabetes Experienced Improved Glycemic Control and Weight Loss 3Monotherapy BYETTA(R) (exenatide) Injection Study Results Presented at ADA 2008 Showed Adults with Type 2 Diabetes Experienced Improved Glycemic Control and Weight Loss 4Monotherapy BYETTA(R) (exenatide) Injection Study Results Presented at ADA 2008 Showed Adults with Type 2 Diabetes Experienced Improved Glycemic Control and Weight Loss 5Monotherapy BYETTA(R) (exenatide) Injection Study Results Presented at ADA 2008 Showed Adults with Type 2 Diabetes Experienced Improved Glycemic Control and Weight Loss 6Monotherapy BYETTA(R) (exenatide) Injection Study Results Presented at ADA 2008 Showed Adults with Type 2 Diabetes Experienced Improved Glycemic Control and Weight Loss 7Synvista Therapeutics Reports Results of Three Phase 2 Clinical Trials of SYI-2074 in Diabetic Patients with Cardiovascular Disease 2Synvista Therapeutics Reports Results of Three Phase 2 Clinical Trials of SYI-2074 in Diabetic Patients with Cardiovascular Disease 3Synvista Therapeutics Reports Results of Three Phase 2 Clinical Trials of SYI-2074 in Diabetic Patients with Cardiovascular Disease 4
AUTION ELEVEN is the eleventh model of AUTION series which is ideal for use in small-to-medium-sized hospitals and clinics with its smart design and features....
Drugs of Abuse (DoA) Array is used for in-vitro diagnostic tests for the qualitative determination of the parent molecule and metabolites of drugs in human urine....
Drugs of Abuse (DoA) Array is used for in-vitro diagnostic tests for the qualitative determination of the parent molecule and metabolites of drugs in human urine....
Stat Detection of Soluble Fibrin Monomer Complexes by the Hemagglutination Technique, 32 tests....
Medicine Products: